Cellectis CLLS 深 沪
已收盘 12-19 16:00:00 美东时间
4.35
+0.190
+4.57%
华盛通- 最 高5.45
- 今 开4.20
- 成交量 7.08万股
- 最 低 3.91
- 昨 收 4.16
- 总市值 1.98亿
- 52周最高 5.4796
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 1.10
- 委 比 -82.94%
- 总股本 4549.08万
- 历史最高 50.00
- 量 比 0.60
- 振 幅 37.02%
- 历史最低 0.9627
- 每 手 1
- 风险率 1.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.
12-17 02:09
Cellectis Earnings Preview
Cellectis (NASDAQ:CLLS) will release its quarterly earnings report on Friday, 2...
11-07 02:03
Monthly information on share capital and company voting rights
Cellectis reports a total of 100,325,229 shares and 89,110,384 voting rights as of May 31, 2025. Further details are available via the provided contacts.
06-05 20:30
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
Cellectis announces its 2025 annual general meeting will be held on June 26, 2025, at 2:30 p.m. CET in Paris, France. The meeting details and reports are available on their website.
05-21 20:30
Cellectis Publishes A 'Molecular Therapy' Article On A SMART DUAL CAR T-Cell Approach For Treating Recalcitrant Solid Tumors
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Molecular Therapy demonstrating TALEN®-mediated gene editing capabilities for design of SMART DUAL ...
2024-08-27 04:34
